http://rdf.ncbi.nlm.nih.gov/pubchem/patent/ES-2261657-T3
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_966a6c1f382ec9bcb5e3839dfd73e5b8 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-455 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-44 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-541 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5377 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-455 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P13-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-44 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D213-75 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00 |
| filingDate | 2002-02-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2006-11-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f88c93f2d045d1d995c20263e5112509 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_92a74618fbf27022391b982ece95c239 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_413d63e8c64dce853befdf279b21c262 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5f71327aa5526926d601a3101e0bc5e5 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_34e0cceeb6772e7a04bbcd17b6940aca http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c83ec19ad8f450f16ce0c26ee850010a |
| publicationDate | 2006-11-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | ES-2261657-T3 |
| titleOfInvention | HYDRAZIDE DERIVATIVES OF PIRROLIDIN-2-CARBOXYL ACID FOR USE AS METALOPROTEASE INHIBITORS. |
| abstract | The use of an NK-1 receptor antagonist for the manufacture of a medicament for the treatment and / or prevention of benign prostatic hyperplasia wherein the NK-1 receptor antagonist is a compound of the general formula (I) (See formula) in which R is hydrogen, C1-7 alkyl, C1-7 alkoxy, halogen or trifluomethyl; R 1 is hydrogen or halogen; or R and R 1 can be together -CH = CH-CH = CH-; R 2 and R 20 are independently from each other, hydrogen, halogen, trifluomethyl, C 1-7 alkoxy or cyano; or R 2 and R 20 may be together -CH = CH-CH = CH-, optionally substituted by one or more substituents selected from C1-7 alkyl, halogen or C1-7 alkoxy; R 3 is hydrogen, C 1-7 alkyl, or forms a cycloalkyl group; R 4 is hydrogen, -N (R 5) 2, -N (R 5) (CH2) nOH, -N (R 5) S (O) 2-C 1-7 alkyl, -N (R 5) S (O ) 2-phenyl, -N = CH-N (R 5) 2, N (R 5) C (O) R 5, a cyclic tertiary amine of the group (See formula) or group (See formula) R 5 is, independently of one another, hydrogen, C 3-6 cycloalkyl, benzyl, phenyl or C 1-7 alkyl; R 6 is hydrogen, hydroxy, C1-7 alkyl, - (CH2) nCOO-C1-7 alkyl, -N (R 5) CO-C1-7 alkyl, hydroxy-C1-7 alkyl, cyano, - (CH2) nO (CH2) nOH, -CHO or a 5- or 6-membered heterocyclic group, optionally linked through an alkylene group; X is -C (O) N (R 5) - or -N (R 5) C (O) -; n is 0, 1, 2, 3 or 4; and pharmaceutically acceptable acid addition salts thereof. |
| priorityDate | 2001-04-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 153.